An easy photochemical approach to the synthesis of the food-borne carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
摘要:
Mutations induced by substances formed during food cooking are a field of growing interest; for a better comprehension of the mechanism of action of these carcinogens, simple routes to their synthesis are needed. In this letter we describe an easy method for 2-amino-1-methyl-6-phenylimidazo[4,5-b]py (PhIP) synthesis, starting from the commercially available 2,3-diaminopyridine 1 via the 2-amino-3-methylamino-5-phenylpyridine 5 formation. The key step of this approach is the one pot synthesis of 5 performed by photolysis of 2-amino-5-iodo-3-(N-methyl-N-tosylamino)pyridine 4 to obtain simultaneous phenylation and tosyl group removal. Compound 5 was then used as an intermediate to obtain the 1-methyl-6-phenylimidazo[4,5-b]pyridine 6 which was aminated to afford PhIP in good overall yields. (C) 1997 Elsevier Science Ltd.
Synthesis and mutagenic potency of structural isomers of 2-amino-1-methyl-6-phenylimidazo[4,5-<i>b</i>]pyridine
作者:W. Chrisman、M. J. Tanga、M. G. Knize
DOI:10.1002/jhet.5570450614
日期:2008.11
Synthesis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), three structuralisomers, and two desphenyl PhIP congeners has been carried out. Mutagenic potency was evaluated using S. typhimurium strain TA98 in the Ames test. Mutagenic potency increased in relation to structural features in these heterocyclic amines that allow extended resonance between the phenyl and imidazo[4,5-b]pyridine
已经进行了2-氨基-1-甲基-6-苯基咪唑并[4,5- b ]吡啶(PhIP),三个结构异构体和两个去苯基PhIP同类物的合成。使用鼠伤寒沙门氏菌菌株TA98在Ames试验中评估致突变力。与这些杂环胺中的结构特征相关的致突变力增加,从而允许苯基和咪唑并[4,5- b ]吡啶N 2-氨基取代基之间的共振延长。相比之下,PhIP异构体的取代不允许苯基参与其氨基咪唑共鸣杂合体,而去苯基同类物的诱变性比PhIP低86-234倍。
Prokineticin 1 receptor antagonists
申请人:Janssen Pharmaceutica N.V.
公开号:EP2385042A1
公开(公告)日:2011-11-09
The present invention relates to certain novel compounds of Formula (I) and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of prokineticin 1 or prokinetin 1 receptor mediated disorders.